Apollon Formularies - Appointment of Medical Director
RNS Number : 2869F
Apollon Formularies plc
15 July 2021

15 July 2021


Apollon Formularies Plc

Appointment of Medical Director

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a medical cannabis company with fully licensed operations in Jamaica, is pleased to announce that Apollon Formularies Jamaica ("Apollon Jamaica") has appointed Dr. Dingle Spence, MBBS, Dip Pall. Med, FRCR, as the Medical Director of its new facility, the Apollon International Cancer Institute, in Kingston, Jamaica, which will be opening shortly. 

This appointment has been made in preparation for the commencement of cancer treatments at the new facility which will provide both Complementary and Alternative Medical (CAM) treatments for cancer, palliative care, and chronic pain patients from Jamaica and international patients travelling to Jamaica as medical tourist patients. 

Dr. Spence is a licensed Jamaican physician specializing in Clinical Oncology, Radiation Therapy, and Palliative Care Medicine for the past 25 years. She continues to work in the public sector at the Hope Institute and Kingston Public Hospitals and is an Associate Lecturer at the University of the West Indies. Dr. Spence is Co-Founder of the non-profit organization the Jamaica Cancer Care and Research Institute (JACCRI) (https://www.jaccri.org/) and is on the Board of Directors of the International Association for Hospice and Palliative Medicine. She is also a consultant expert to the International Atomic Energy Agency (IAEA) and currently sits on two Lancet Commissions dedicated to improving cancer care and health care globally.

Stephen D. Barnhill, M.D., CEO of Apollon, commented, "Apollon is pleased to announce our expansion to begin treating cancer patients at our new Apollon International Cancer Institute in Kingston, Jamaica, while continuing to treat patients at the Negril, Jamaica treatment facility, which will allow us to help more patients and generate additional revenue. We are excited to be providing patients with our proprietary medical cannabis formulations, recently shown to successfully kill cancer cells in 3D cell culture in independent third-party pre-clinical laboratory testing at BIOENSIS laboratories, the premier provider of 3D Cellular Pharmacology Services in the United States

"We are honoured to have Dr. Dingle Spence as our Medical Director. She has tremendous expertise in clinical oncology, radiation therapy, palliative care, and pain control, as well as in using medical cannabis in these clinical settings. Dr. Spence is also a dedicated and compassionate physician." 

Dr. Dingle Spence, Medical Director of Apollon's International Cancer Institute, stated "I am delighted to be working with the team at Apollon's International Cancer Institute and look forward to offering an integrated approach with Complementary and Alternative Medical treatments for cancer, palliative care and chronic pain patients. We are excited to be offering Apollon's medical cannabis formulations, which will be available by prescription, in our current treatment protocols. In addition, as allowed under Apollon Jamaica's Cannabis Licensing Authority (CLA) approved Research and Development Licence we also intend to perform clinical trials with the approval of the Ministry of Health and Wellness (MOHW) to collect patient clinical data to support the successful results seen with the Apollon medical cannabis formulations in the pre-clinical laboratory testing."

- End -




For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies                                                     

Tel:                                         +44 207 907 9314

Stene Jacobs                      stene@apollon.org.uk 



Peterhouse Capital Limited (Corporate Adviser)             

Tel:                                         +44 207 220 9795

Guy Miller                           gm@peterhousecapital.com


Blytheweigh (Financial PR/IR-London)                 

Tel:                                         +44 207 138 3204

Tim Blythe                           tim.blythe@blytheweigh.com

Megan Ray                         megan.ray@blytheweigh.com 


About Apollon Formularies plc

Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual affiliate of Apollon.  Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to purchase cannabis under tripartite agreements from licensed cultivators, process, perform research and development, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision.



BIOENSIS is the solution of choice of predictive pharmacology needs led by a scientific team with more than 40 years of combined experience in preclinical pharmacology. BIOENSIS is the premiere innovator of 3D pharmacology technologies that more accurately recapitulate the microenvironment of human tissues and tumours. Their cutting-edge technology has been validated and optimized in more than 130 cell lines and primary tissues, and their flexible technology enables assay customization and optimization for additional cell lines and organ tissues. They have a demonstrated track record of unparalleled commitment to and collaboration with customers to achieve their predictive pharmacology objectives.


Stephen D. Barnhill, M.D.

Dr. Barnhill is a physician, fellowship trained in Laboratory Medicine and an expert in Artificial Intelligence (AI), an inventor on more than 40 patents globally and a pharmaceutical and biotech executive with experience as a CEO in both private and public companies in the United States and internationally. Dr. Barnhill is the Chairman and CEO of Apollon and the President and a 49% shareholder of Apollon Jamaica, which shares he holds for the benefit of Apollon. Dr. Barnhill is also the Executive Chairman of Aion and serves as a director and executive officer of AI Pharma.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.